Article
Integration of cytogenetic and molecular alterations in risk stratification of 318 patients with de novo non-M3 acute myeloid leukemia.
Leukemia - 1 Jan 2014
Hou H A, Lin C C, Chou W C, Liu C Y, Chen C Y, Tang J L, Lai Y J, Tseng M H, Huang C F, Chiang Y C, Lee F Y, Kuo Y Y, Lee M C, Liu M C, Liu C W, Lin L I, Yao M, Huang S Y, Ko B S, Hsu S C, Wu S J, Tsay W, Chen Y C, Tien H F
Abstract excerpt
Conventionally, acute myeloid leukemia (AML) patients are categorized into good-, intermediate- and poor-risk groups according to cytogenetic changes. However, patients with intermediate-risk cytogenetics represent a largely heterogeneous population regarding treatment response and clinical outcome. In this study, we integrated cytogenetics and molecular mutations in the analysis of 318 patients with de novo...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.